Whitehawk Therapeutics, Inc.
WHWK evidence brief
What we can confirm
- BioSniper Score:
- 6.3 / 10
- Market Cap:
- $234.3M
- Lead Asset:
- fyarro (Phase 2)
What it means
What to watch
Prepared research question
What matters most for WHWK—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · WHWK
Whitehawk Therapeutics, Inc. is a clinical-stage oncology company developing antibody-drug conjugates (ADCs) and has one marketed product, FYARRO (nab-sirolimus), for advanced PEComa.
Key risk: No revenue, net loss
BioSniper Score
Based on 4 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 4 pipeline candidates · 2 clinical trials · 1 catalyst for Whitehawk Therapeutics, Inc..
Similar companies
Whitehawk Therapeutics, Inc. is a clinical-stage oncology company developing antibody-drug conjugates (ADCs) and has one marketed product, FYARRO (nab-sirolimus), for advanced PEComa.
- Cash & equivalents of $85.2M as of 2026-06-30 [sec].
- Total revenue of $0.0M and net income of -$16.6M as of 2026-06-30 [sec].
- Phase 1 trials for HWK-007 (PTK7-directed ADC) and HWK-016 (MUC16-directed ADC) are actively recruiting; data readouts expected in first half of 2027 [sec_mda · as of 2026-05-07].
- IND for HWK-206 (biparatopic ADC targeting SEZ6) is anticipated to be cleared by the FDA in mid-2026 [sec_mda · as of 2026-08-06].
- Entered into a global collaboration with Biocytogen in June 2026 to develop bispecific antibody-drug conjugates [sec_mda · as of 2026-08-06].
What works
- Strong cash position of $85.2M as of 2026-06-30 provides runway for ongoing Phase 1 trials and pipeline expansion [sec].
- Multiple ADC programs in Phase 1 (HWK-007, HWK-016) with a third (HWK-206) expected to enter the clinic soon, targeting large oncology indications [sec_mda · as of 2026-05-07].
- Recent strategic collaborations (Hangzhou DAC option agreement, Biocytogen BsADC collaboration) expand the company's ADC pipeline without diluting global rights [sec_mda · as of 2026-08-06].
- Management team has extensive experience in oncology drug development and commercialization [sec_mda · as of 2026-08-06].
What to weigh
- No revenue generated as of 2026-06-30, with a net loss of $16.6M in the latest reported period [sec].
- All pipeline candidates are in early Phase 1 trials; no clinical data have been reported yet, and data readouts are not expected until the first half of 2027 [sec_mda · as of 2026-05-07].
- The company relies on external partners (WuXi Biologics, Hangzhou DAC, Biocytogen) for key ADC technology and manufacturing, creating dependency risks [sec_mda · as of 2026-05-07].
- Patent expiry for FYARRO (sirolimus) is scheduled for 2040-10-28, which could eventually affect the only commercialized product's exclusivity [catalyst].
From the filings
Quoted directly from source documents.
Phase 1 trials for HWK-007 and HWK-016 are actively recruiting with data readouts expected in first half of 2027
“The FDA has cleared the IND applications for HWK-007 and HWK-016 and the Phase 1 trials for each asset are now actively recruiting. We expect data readouts in the first half of 2027 for each trial.”
SEC MD&A · May 7, 2026
IND for HWK-206 anticipated in mid-2026
“We anticipate FDA clearance of our IND for HWK-206 for the treatment of small cell lung cancer ("SCLC") and neuroendocrine tumors ("NETs") in mid-2026.”
SEC MD&A · August 6, 2026
Collaboration with Biocytogen for bispecific ADCs
“in June 2026, we entered into a global collaboration with Biocytogen to develop bispecific antibody-drug conjugates ("BsADC").”
SEC MD&A · August 6, 2026
Catalyst timeline
- 2040-10-28 · Patent_Expiry · SIROLIMUS — Patent expiry for NDA213312 (FYARRO/sirolimus); may affect exclusivity of the company's only commercialized product.
Risks & what to watch (4)›
Key risks
- No revenue, net loss — Zero revenue and $16.6M net loss as of 2026-06-30; company is pre-revenue and dependent on cash reserves [sec].
- Early-stage pipeline — All candidates are in Phase 1; no clinical data available yet, with first readouts not expected until H1 2027 [sec_mda · as of 2026-05-07].
- Partner dependency — Key ADC technology and manufacturing rely on partners (WuXi, Hangzhou DAC, Biocytogen), creating execution and IP risks [sec_mda · as of 2026-05-07].
- Patent expiry for FYARRO — Patent for FYARRO (sirolimus) expires 2040-10-28, potentially affecting long-term product exclusivity [catalyst].
What to watch
- FDA clearance of IND for HWK-206, expected mid-2026 [sec_mda · as of 2026-08-06].
- Phase 1 data readouts for HWK-007 and HWK-016, expected in the first half of 2027 [sec_mda · as of 2026-05-07].
- Submission of IND applications for new ADC programs under the Hangzhou DAC option agreement, anticipated over the next 12-24 months [sec_mda · as of 2026-08-06].
- Progress of the Biocytogen bispecific ADC collaboration, announced in June 2026 [sec_mda · as of 2026-08-06].
Sources: Catalysts · Pipeline · SEC MD&A · Generated October 13, 2026 · How we verify sources →
Run Whitehawk Therapeutics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Whitehawk Therapeutics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
Cash runway data unavailable
D/E 0.06 · 0% dilution
Lead: Phase 2
4 candidates
1 upcoming, next in ~5128d
No insider transactions in the last 180 days
Catalysts
Pipeline
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
62
Total value held
$122.4M
| Holder | Shares | Value |
|---|---|---|
| qvt financial lp | 4,615,709 | $15.9M |
| orbimed advisors llc | 4,166,000 | $14.4M |
| suvretta capital management, llc | 3,700,000 | $12.8M |
| acuta capital partners, llc | 3,410,402 | $11.8M |
| avoro capital advisors llc | 2,849,402 | $9.8M |
| kvp capital advisors, lp | 2,165,997 | $7.5M |
| siren, l.l.c. | 2,082,000 | $7.2M |
| yu fan | 2,070,000 | $7.1M |
| stempoint capital lp | 1,878,738 | $6.5M |
| vanguard capital management llc | 1,315,770 | $4.5M |
Showing top 10 of 62 institutional holders of Whitehawk Therapeutics, Inc.. Open the full 13F history after sign-in.
Short Interest
as of Apr 28, 2026- % of float
- 2.2%
- Days to cover
- 4.0
- Shares short
- 780,056
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
WHWK short interestGovernance
Frequently asked questions
What is the AI investment thesis for Whitehawk Therapeutics, Inc.?
Whitehawk Therapeutics, Inc. is a clinical-stage oncology company developing antibody-drug conjugates (ADCs) and has one marketed product, FYARRO (nab-sirolimus), for advanced PEComa.
What is Whitehawk Therapeutics, Inc.'s lead drug candidate?
Whitehawk Therapeutics, Inc.'s most advanced tracked candidate is fyarro (Phase 2) for Neuroendocrine tumors (NETs) of the GI tract, lung, or pancreas.
What is Whitehawk Therapeutics, Inc.'s next catalyst?
Whitehawk Therapeutics, Inc.'s next tracked catalyst is a Patent_Expiry event — "Patent_Expiry: NDA213312" — expected October 28, 2040.
Who is the CEO of Whitehawk Therapeutics, Inc.?
Dr. David J. Lennon Ph.D. is the chief executive officer of Whitehawk Therapeutics, Inc. (WHWK).
Where is Whitehawk Therapeutics, Inc. headquartered?
Whitehawk Therapeutics, Inc. (WHWK) is headquartered in Morristown, NJ, United States.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.